Journal: PLoS ONE

Article Title: A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery

doi: 10.1371/journal.pone.0066967

Figure Lengend Snippet: Growth kinetics of P. berghei following intravenous infection of (A) immunocompetent CD1 or (B) immunodeficient NSG mice is shown. The plots show the parasitemia in peripheral blood of female mice infected with 0.1×10 6 , 1×10 6 , 10×10 6 , and 50×10 6 infected erythrocytes. The dashed line (P 0 ) indicates the target human-equivalent parasitemia. Data are the mean ± standard deviation of n = 4 mice/group. Error bars are shown only if they are bigger than symbols.

Article Snippet: Experimental and control animals were specific pathogen-free 8–12-week-old females, body weight range 20–22 g. CD1 Swiss (Hsd:ICR) mice were obtained from Harlan Interfauna (Iberica, Spain) and immunodeficient NSG (NOD.Cg -Prkdc scid Il2rg tm1Wjl /Sz) mice from Charles River Laboratories (L’Arbresle, France under license of The Jackson Laboratory, Bar Harbor, Maine, USA).

Techniques: Infection, Standard Deviation

Journal: PLoS ONE

Article Title: A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery

doi: 10.1371/journal.pone.0066967

Figure Lengend Snippet: The plots show the kinetics of parasitemia in peripheral blood of CD1 female mice infected with 10×10 6 infected erythrocytes at day 0 and treated at days 2 and 3 (downward arrows) with a set of antimalarial drugs used for validation of the P. berghei ED 90 -normalized in vivo assay. For clarity, only selected doses are explicitly indicated in the plot. Data are the mean ± standard deviation of n = 3 mice/group. Error bars are shown only if they are bigger than symbols.

Article Snippet: Experimental and control animals were specific pathogen-free 8–12-week-old females, body weight range 20–22 g. CD1 Swiss (Hsd:ICR) mice were obtained from Harlan Interfauna (Iberica, Spain) and immunodeficient NSG (NOD.Cg -Prkdc scid Il2rg tm1Wjl /Sz) mice from Charles River Laboratories (L’Arbresle, France under license of The Jackson Laboratory, Bar Harbor, Maine, USA).

Techniques: Infection, Biomarker Discovery, In Vivo, Standard Deviation

Journal: PLoS ONE

Article Title: A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery

doi: 10.1371/journal.pone.0066967

Figure Lengend Snippet: Evaluation of PRR 48h allowed validation of the Plasmodium berghei ED 90 -normalized in vivo assay in vehicle-treated control animals and against human data. (A) Correlation between the log 10 [PRR 48h ] and the distance between top and bottom values of the logistic fit calculated in for each control antimalarial in CD1 mice infected with P. berghei . (B) Correlation of log 10 [PRR 48h ] between CD1 mice infected with P. berghei in the screening assay format and humans infected with P. falciparum . Data on log 10 [PRR 48h ] in humans are taken from – .

Article Snippet: Experimental and control animals were specific pathogen-free 8–12-week-old females, body weight range 20–22 g. CD1 Swiss (Hsd:ICR) mice were obtained from Harlan Interfauna (Iberica, Spain) and immunodeficient NSG (NOD.Cg -Prkdc scid Il2rg tm1Wjl /Sz) mice from Charles River Laboratories (L’Arbresle, France under license of The Jackson Laboratory, Bar Harbor, Maine, USA).

Techniques: Biomarker Discovery, In Vivo, Control, Infection, Screening Assay